DAS-181 is under clinical development by Ansun Biopharma and currently in the Phase I, Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect DAS-181’s likelihood of approval (LoA) and phase transition for Enterovirus Infections took place on 28 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

In addition, the same event on 28 Dec 2022 increased DAS-181’s Phase Transition Success Rate (PTSR) for Metapneumovirus Infections.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their DAS-181 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

DAS-181 overview

DAS-181 is under development for the treatment of influenza A virus,H1N1 and H3N2 subtype, influenzavirus B,enterovirus, beta corona virus infections including COVID-19 infections, metapneumovirus and lower respiratory tract infection due to parainfluenza type 3 virus infections in immunocompromized patients. The drug candidate is a nebulized drug formulation which is administered inhalationally as a dry powder. It is a recombinant fusion protein consisting of a sialidase catalytic domain (derived from Actinomyces viscosus sialidase) and an epithelial surface-anchoring heparin-binding domain derived from the human protein amphiregulin. It was also under development for asthma, pandemic influenza and bronchiectasis.

Ansun Biopharma overview

Ansun Biopharma is a biopharmaceutical company which develops biologic therapeutics to treat unmet medical needs and respiratory infections. The company’s product pipeline includes DAS181, a sialidase enzyme being developed to treat parainfluenza, influenza, metapneumovirus and Enterovirus68, a cause of mild infectious illnesses. It also develops solutions to cure pandemic flu strains. The company is funded by 3E Bioventures, Lilly Asia Ventures, Lyfe Capital, VI Ventures and others. Ansun Biopharma is headquartered in San Diego, California, the US.

Quick View DAS-181 LOA Data

Report Segments
  • Innovator
Drug Name
  • DAS-181
Administration Pathway
  • Inhalational
Therapeutic Areas
  • Infectious Disease
  • Respiratory
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.